NFE2L2 and plasma cell myeloma: Nrf2 expression was lowest in the proliferation subgroup (PR), which represents patients with the poorest prognosis (p < 0.001; Fig. 3b) and was significantly decreased in high-risk myeloma samples (p = 0.0002; Fig. 3c).